Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 10/20 | 0.55 |
| ▸ | RORC | P51449 | 10/20 | 0.55 |
| ▸ | RORB | Q92753 | 10/20 | 0.55 |
| ▸ | PGR | P06401 | 9/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29034 | 0.89 | KDM4E (0.54) | RORARORCRORBPGRNR1H2 | |
| SCHEMBL15473627 | 0.81 | KIF11 (0.49) | RORARORCRORBPGRKDM4E | |
| SCHEMBL29667 | 0.80 | POLB (0.50) | RORARORCRORBKDM4ELMNA | |
| SCHEMBL30795727 | 0.80 | POLB (0.50) | RORARORCRORBKDM4ELMNA | |
| SCHEMBL30795913 | 0.77 | CNR2 (0.47) | KDM4ELMNASMN1; SMN2POLB | |
| SCHEMBL29819 | 0.77 | CNR2 (0.47) | KDM4ELMNASMN1; SMN2POLB | |
| SCHEMBL29431171 | 0.76 | RORA (0.54) | RORARORCRORBPGRNR1H2 | |
| SCHEMBL21915049 | 0.76 | RORA (0.54) | RORARORCRORBPGRNR1H2 | |
| SCHEMBL15473646 | 0.74 | RORA (0.47) | RORARORCRORBPGRNR1H2 | |
| SCHEMBL715426 | 0.74 | KIF11 (0.47) | RORCKDM4EHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103189357-B | Substituted 2-oxo-and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| EP-2609086-B1 | SUBSTITUTED 2-OXO- AND 2-THIOXO-DIHYDROQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-8653102-B2 | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2609086-A1 | SUBSTITUTED 2-OXO- AND 2-THIOXO-DIHYDROQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| CN-103189357-A | Substituted 2-oxo-and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH | 2013-07-03 | — | — | CN | disclosed |
| US-20120053206-A1 | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2012025239-A1 | SUBSTITUTED 2-OXO- AND 2-THIOXO-DIHYDROQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053206-A1 | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | RORA 913/4885RORC 903/4885RORB 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.